Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tilarginine - Nova Pharmaceuticals

Next Previous
Drug Profile

Tilarginine - Nova Pharmaceuticals

Alternative Names: 546C88; ANO-1020; BW546C88; L-NMMA; N-Monomethyl-arginine; NMA; TAI

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell Research Foundation; Houston Methodist Hospital; M. D. Anderson Cancer Center
  • Developer Arginox Pharmaceuticals; Galera Therapeutics; Houston Methodist Hospital
  • Class Antihypotensives; Basic amino acids; Diamino amino acids; Small molecules; Vascular disorder therapies
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiogenic shock
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Triple negative breast cancer
  • Phase I/II HER2 negative breast cancer
  • Discontinued Cancer; Cardiogenic shock; Hypotension; Kidney disorders; Rheumatoid arthritis; Septic shock; Transplant rejection

Most Recent Events

  • 07 Jan 2025 Phase-II clinical trials in Triple-negative-breast-cancer (Combination therapy) in USA (IV) before January 2025 (Galera therapeutics pipeline January 2025)
  • 01 Jan 2025 Efficacy data from a phase I/II trial in Triple negative breast cancer was released by Galera Therapeutics
  • 12 Jan 2023 Phase-I/II clinical trials in HER2-negative-breast-cancer (Metastatic disease, Combination therapy, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT05660083)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top